Secreto G, Recchione C, Fariselli G, Di Pietro S
Cancer Res. 1984 Feb;44(2):841-4.
Serum testosterone, progesterone, luteinizing hormone, prolactin, and sex hormone-binding globulin levels were measured in 55 normal controls, in 31 patients with hyperplastic alterations of breast epithelium, and in 23 patients with breast cancer. All patients and controls were premenopausal, and they were comparable for age, weight, and body surface. In the controls, the mean level of testosterone [0.47 +/- 0.16 (S.D.) ng/ml] was lower and the mean level of progesterone (17.63 +/- 8.11 ng/ml) was higher than in breast cancer patients [testosterone level, 0.62 +/- 0.22 ng/ml (p less than 0.005); progesterone level, 11.4 +/- 8.0 ng/ml (p less than 0.005)] and in patients with breast epithelial hyperplasia [testosterone level, 0.55 +/- 0.2 ng/ml (p less than or equal to 0.05); progesterone level, 13.9 +/- 8.6 ng/ml (p less than 0.05)]. No difference was found in the mean circulating levels of luteinizing hormone, prolactin, or sex hormone-binding globulin between controls and patients. These results confirm previous findings of increased urinary testosterone excretion in women with anovulatory menstrual cycles and epithelial hyperplasia or cancer of the breast and strongly support the hypothesis that androgens play an important role in both induction and development of breast cancer.
对55名正常对照者、31名乳腺上皮增生性改变患者和23名乳腺癌患者测定了血清睾酮、孕酮、促黄体生成素、催乳素和性激素结合球蛋白水平。所有患者和对照者均处于绝经前，且在年龄、体重和体表面积方面具有可比性。在对照组中，睾酮的平均水平[0.47±0.16（标准差）ng/ml]低于乳腺癌患者[睾酮水平，0.62±0.22 ng/ml（p<0.005）]和乳腺上皮增生患者[睾酮水平，0.55±0.2 ng/ml（p≤0.05）]，而孕酮的平均水平（17.63±8.11 ng/ml）高于乳腺癌患者[孕酮水平，11.4±8.0 ng/ml（p<0.005）]和乳腺上皮增生患者[孕酮水平，13.9±8.6 ng/ml（p<0.05）]。对照组与患者之间促黄体生成素、催乳素或性激素结合球蛋白的平均循环水平未发现差异。这些结果证实了先前关于无排卵月经周期以及乳腺上皮增生或癌症女性尿睾酮排泄增加的研究发现，并有力支持了雄激素在乳腺癌的诱导和发展中起重要作用这一假说。
